- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterHighlights from the 2006 AACR Plenary Session
OncoLink's John Plastaras, MD reports on the April 1-5, 2006 meeting "Breakthroughs in Clinical Research" in Washington DC.
|
A phase III, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer
Presenter: Marc Peeters Presenter's Affiliation: Ghent University Hospital, Ghent, Belgium Type of Session: Clinical Plenary Background Epidermal growth factor receptor (EGFR) signaling contributes to tumor growth, and overexpression of... |
|
|
Celecoxib reduces sporadic colorectal adenomas: Results from the Adenoma Prevention with Celecoxib (APC) trial
Presenter: Monica M. Bertagnolli Presenter's Affiliation: Brigham and Women's Hospital, Boston, MA Type of Session: Clinical Plenary Background Cyclooxygenase-2 (COX-2) converts arachidonic acid to prostaglandin endoperoxides, which in... |
|
|
Chemoprevention of colorectal adenomas with celecoxib in an international, randomized, placebo-controlled, double-blind trial
Presenter: Nadir Arber Presenter's Affiliation: Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel Presenter's Financial Interest Disclosure: Pfizer and GI View Type of Session: Clinical Plenary Background Cyclooxygenase-2 (COX-2)... |
|
|
Development of the ABL kinase inhibitor dasatinib (BMS-354825) in imatinib-resistant Philadelphia chromosome-positive leukemias
Presenter: Charles L. Sawyers Presenter's Affiliation: University of California at Los Angeles, Los Angeles, CA Type of Session: Clinical Plenary Background Chronic myeloid leukemia (CML) is associated with the 9;22 reciprocal... |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
